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Biliary brush cytology is the standard method of sampling a biliary stricture but has a low sensitivity for the detection of malignancy.
We have previously shown that minichromosome maintenance (MCM) replication proteins (Mcm2–7) are markers of dysplasia and
have utilised these novel biomarkers of growth for the diagnosis of cervical and bladder cancer. We aimed to determine if MCM
proteins are dysregulated in malignant pancreaticobiliary disease and if levels in bile are a sensitive marker of malignancy. In 30 tissue
specimens from patients with malignant/benign biliary strictures, we studied Mcm2 and -5 expression by immunohistochemistry. Bile
samples were also collected prospectively at endoscopic retrograde cholangiopancreatography from 102 consecutive patients with
biliary strictures of established (n¼42) or indeterminate aetiology (n¼60). Patients with indeterminate strictures also underwent
brush cytology as part of standard practice. Bile sediment Mcm5 levels were analysed using an automated immunofluorometric assay.
In benign biliary strictures, Mcm2 and -5 protein expression was confined to the basal epithelial proliferative compartment – in
contrast to malignant strictures where expression was seen in all tissue layers. The percentage of nuclei positive for Mcm2 was higher
in malignant tissue (median 76.5%, range 42–92%) than in benign tissue (median 5%, range 0–33%) (Po0.0005), with similar results
for Mcm5. Minichromosome maintenance protein 5 levels in bile were significantly more sensitive than brush cytology (66 vs 20%;
P¼0.004) for the detection of malignancy in patients with an indeterminate stricture, with a comparable positive predictive value (97
vs 100%; P¼ns). In this study, we demonstrate that Mcm5 in bile detected by a simple automated test is a more sensitive indicator of
pancreaticobiliary malignancy than routine brush cytology.
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The diagnosis of pancreatic and biliary tract cancer at an early
stage of disease remains difficult and there are currently no
established methods of surveillance for biliary tract cancer in
patients with primary sclerosing cholangitis (PSC). Current
diagnostic modalities include serum tumour markers and imaging
but are not specific enough to allow for confident confirmation of
malignancy especially in its early stages and therefore cytological/
biopsy specimens are usually acquired from biliary strictures/
masses (Lee, 2006). Brush cytology is the most commonly used
method of sampling a biliary stricture (De Bellis et al, 2002a) as it
is relatively easy to perform, does not compromise resection
margins in potentially resectable cases and has a high specificity
(96–100%) for malignancy. However, cytology has a low
sensitivity (9–57%) (de Bellis et al, 2002b; Baron et al, 2004;
Harewood et al, 2004; Moreno Luna et al, 2006) for the detection of
malignancy, which is even lower if cells are acquired from bile
aspirates (6–32%) (De Bellis et al, 2002a). The poor detection rate
may stem from a number of factors, including the desmoplastic
nature of biliary tract cancers, failure to obtain an adequate
cellular yield and morphological changes induced by inflammation
and necrosis. Furthermore, to some extent, the interpretation of
cytological specimens is subjective and observer-dependent and
more accurate quantitative tests would be desirable.
Despite the detection of several molecular genetic alterations
in pancreatic and biliary tract cancer, their reported low frequency
in biological samples has limited their usefulness as diagnostic
markers (Gress, 2004). For example, neither K-Ras nor p53
mutational analysis has been shown to be superior to conventional
cytopathology for the diagnosis of pancreaticobiliary tumours
(Khan et al, 2005).
The initiation of DNA replication represents a final and critical
step in growth regulation and lies downstream at the convergence
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spoint of growth regulatory pathways (Williams and Stoeber, 1999).
Minichromosome maintenance proteins (Mcm2–7) participate in
the assembly of prereplicative complexes to establish competence
for initiation of DNA synthesis (DNA replication licensing). All six
Mcm proteins are essential for replication, are present in all phases
of the proliferative cell cycle but are tightly downregulated in the
quiescent, terminally differentiated and senescent ‘out-of-cycle’
states. The presence of one protein reflects the presence of the
other five as all six are loaded together onto DNA as a
heterohexamer on exit from metaphase (Blow and Hodgson,
2002) . We have shown that these biomarkers detect, in addition to
actively proliferating cells, cells with growth potential (Stoeber
et al, 2001). We have also shown that dysregulation of MCM
proteins is an early event in epithelial carcinogenesis, which occurs
in a wide range of preneoplastic and neoplastic states (Freeman
et al, 1999) resulting in exfoliation of MCM-positive tumour cells.
Moreover, we have utilised these novel biomarkers of growth as
diagnostic markers of cervical, genitourinary tract and oesopha-
geal cancer (Williams et al, 1998, 2004; Stoeber et al, 1999, 2002).
On the basis of these data in other solid-organ tumours, we
proposed that detection of MCM proteins in exfoliated tumour
cells might be a potentially sensitive indicator of pancreaticobiliary
neoplasia. Here we describe a novel automated liquid-phase
immunofluorometric assay to quantify Mcm5 levels in biliary
aspirates obtained from patients undergoing endoscopic retro-
grade cholangiopancreatography (ERCP) for the diagnosis and
treatment of biliary strictures.
METHODS
Patients
Between 2004 and 2006, 113 consecutive patients were invited to
participate in the study for evaluation of indeterminate, or
established, benign and malignant biliary tract strictures. Seven
patients were excluded due to inability to sedate the patient
adequately (n¼3), bile not aspirated (n¼2), ampulla not
identified (n¼1) or patient did not agree to participate in the
study (n¼1). A total of 106 patients underwent ERCP with
aspiration of bile for Mcm5 analysis and parallel biliary brush
cytology obtained as part of routine diagnostic practice in
indeterminate strictures. Four patients were excluded after bile
collection as we did not have access to sufficient follow-up
information to be confident of a diagnosis. Therefore, a total of 102
patients were included in the study. A diagnosis of malignancy was
made by positive cytology/biopsy or evidence of disease progres-
sion on imaging. Benign disease was established by negative
pathology and a median of 39 (range 21–48) months clinical
follow-up. The study was approved by the Joint UCLH/UCL ethical
committee and all patients gave written informed consent.
Brush cytology of biliary strictures
If a stricture of indeterminate aetiology was present at ERCP,
biliary brush cytology was collected by standard technique. A wire-
guided sheathed cytology brush (Combocath, Microinvasive;
Boston Scientific, Notick, MA, USA) was advanced across the
stricture several times before being resheathed and the sheathed
brush withdrawn from the endoscope. The cytology specimen was
then transferred immediately to glass slides by smearing the
cellular material from the brush directly onto two slides. These
were fixed and later stained for malignant cells using the standard
Papanicolaou technique for smears. Brush cytology samples were
analysed by expert cytopathologists within the context of a
multidisciplinary cancer review meeting. Cytology was classified
as malignant or no definitive evidence of malignancy (highly
suspicious, low-grade dysplasia, inflammatory, normal).
Immunohistochemistry
Formalin-fixed archival blocks were selected from the files at
University College London Hospital. Sections (4mm) were cut
using a sledge microtome and placed onto Superfrost Plus slides.
After drying the slides overnight at 601C, sections were depar-
affinised in xylene and rehydrated in water. Antigen retrieval was
performed by pressure cooking sections in 0.1mmoll
 1 citrate
buffer (pH 6.0) at 15 p.s.i. (103.4kPa) for 2min.
Tissue sections cut on to Superfrost Plus slides were stained
manually or using a standard protocol, as described below.
Following antigen retrieval, the slides were washed thrice (using
Tris buffered saline with 0.1% Tween 20 for this and subsequent
washes). Endogenous peroxidase activity was quenched with
peroxidase-blocking solution (DAKO, Ely, UK) for 15min.
Sections were incubated with primary antibody for 45min. Mouse
anti-human monoclonal Mcm2 and rabbit anti-human polyclonal
Mcm5 antibodies were obtained from BD Transduction Labora-
tories (Lexington, KY, USA). The slides were incubated with the
secondary antibody for 2h and developed with 3,3-diaminobenzi-
dine for 10min. Slides were then counterstained with Mayer’s
haematoxylin, differentiated in 1% acid alcohol, dehydrated and
cleared in xylene. Coverslips were applied with Leica CV Mount
(Leica, Nussloch, Germany). Incubation without the primary
antibody was used as a negative control and colonic epithelial
sections were used as positive controls. Those sections mounted on
DAKO ChemMate capillary gap slides were stained using the
DAKO TechMate 500 immunostainer (DAKO, Cambridge, UK).
Microscopic images were acquired with an Olympus BX51 light
microscope/CCD camera setup and ANAlysis image-capturing
software (Soft Imaging Systems GmbH, Munster, Germany). A
semiquantitative determination of the extent of staining was
obtained by calculating a labelling index for each protein stained.
At least 200 epithelial nuclei were assessed per case. Results were
expressed as a percentage of positively stained nuclei out of the
total number of nuclei counted in representative microscopic
fields. The median and range of labelling indices were calculated.
Bile aspirate collection and storage
After biliary brushing, 5–10ml of bile was aspirated from directly
above the stricture via a standard ERCP catheter. Storage buffer
(10  phosphate-buffered saline (PBS), 5% bovine serum albumin,
1 M sucrose, 0.2% NaN3) containing one complete mini EDTA-free
protease inhibitor cocktail tablet (Roche Diagnostics Ltd, Lewes,
East Sussex, UK) per 10ml of buffer was added to bile aspirates at
one-tenth aspirate volume and mixed with the sample. Bile
aspirates in storage buffer were transferred into 15ml cryovials,
placed in dry ice and stored at  801C within 6h.
Processing of standards and bile aspirates
Aspirates were analysed in a blinded manner for immunofluoro-
metric Mcm5 detection. Standards for the immunofluorometric
Mcm5 assay were prepared by serial dilution of lysates from
asynchronous HeLa S3 cultures to 1500, 5000, 15000, 50000 and
150000 cells per well. Standards and bile samples were processed
as described previously (Stoeber et al, 2002). Briefly, standards and
clinical samples were thawed, and the cells were isolated by
centrifugation at 1500g for 5min at 41C. The supernatants were
discarded, and the cell pellets were washed three times with 500ml
of PBS. Cell pellets were resuspended in 250ml of processing buffer
(PBS, 0.4% sodium dodecyl sulphate (SDS), 0.02% NaN3). Cell
lysates were prepared by incubating the resuspended samples at
951C for 45min. The DNA in each sample was sheared by passing
the lysates through a 21-gauge needle (Terumo Europe NV,
Leuven, Belgium), and nucleic acids were digested with DNase I
(20Uml
 1; Roche Diagnostics) and RNase A (1mgml
 1;
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sSigma-Aldrich UK Ltd, Dorset, UK) for 2h at 371C. The samples
were centrifuged at 15000g for 10min to pellet the cell debris, the
supernatants were collected and 50ml of each was directly used in
the immunofluorometric assay.
Automated immunofluorometric measurement of Mcm5
levels in bile aspirates
Monoclonal antibodies (MAbs) 12A7 and 4B4 raised against
His-tagged human Mcm5 were protein A-purified from hybridoma
supernatants as described previously (Stoeber et al, 2002). Protein
A-purified MAb 4B4 was labelled with europium using a DELFIA
Eu-labelling kit (Perkin-Elmer Life Science, Wallac Oy, Turku,
Finland) according to the manufacturer’s instructions. The assay
was standardised using HeLa cells as described above and
previously (Stoeber et al, 2002), and one fluorescence unit was
defined as the signal generated by the Mcm5 contents of one
proliferating HeLa S3 cell, approximately 10
5 Mcm5 molecules
(Kearsey and Labib, 1998). DELFIA research reagents were
obtained from Perkin-Elmer Life Science. Multibuffer was
prepared from 0.2 vol 5  DELFIA assay buffer (Perkin-Elmer),
0.125 vol DELFIA TSH-Ultra assay buffer (Perkin-Elmer) and 0.1
vol Tween 20 (Sigma). All other reagents were obtained from
Sigma-Aldrich. Immunofluorometric measurements of Mcm5
levels were performed as described previously (Stoeber et al,
2002). Standard curves were constructed from fluorescence values
generated by the blank and standard wells, and the fluorescence
values of the bile aspirate samples were calculated with the
Multicalc Advanced Immunoassay Data Management package
(Perkin-Elmer Life Science). The reliability of the test was
maintained by assaying the Mcm5 content of a known number
of HeLa cells as an internal standard when bile samples were
assayed.
For immunofluorometric measurement of Mcm5 levels, assay
standards, control samples and bile aspirate samples were run as
duplicates and the mean of the duplicate results reported. For
acceptance of immunofluorometric measurements in the assay, the
following coefficients of variations were required: CVo20% for
results between 1500 and 5000 cells per well standard curve points;
CVo15% for results between 5000 and 15000 cells per well; and
CVo10% for results 415000 cells per well. On completion of the
study, patient data were decoded and the immunofluorometric
signals compared with biliary brushing results.
Immunoassay performance
In our analysis, we used 1000 cells per well as the lower detection
limit because the within-batch coefficient of variation of the assay
was less than 25% in all samples with cell dilutions above 1000 cells
per well, but in only one-quarter of samples below this limit.
Samples that generated a fluorescence signal below that corres-
ponding to 1000 cells per well were reported as having fewer than
1000 cells per well.
Statistical analysis
Sensitivity and specificity characteristics of the immunofluoro-
metric Mcm5 test for the detection of pancreaticobiliary malig-
nancy were presented as a receiver operating characteristics (ROC)
curve. The area under the nonparametric ROC curve was used to
assess the overall accuracy of the test. Two cut points were used to
demonstrate test performance under different circumstances as
follows: (i) at the lower detection limit of the assay (i.e. 1000 cells
per well), where sensitivity of the test was maximal and (ii) where
specificity was 100% (i.e. 1780 cells per well). An exact 95%
confidence interval (CI) for each proportion, including sensitivity,
specificity and predictive values of Mcm5 and cytology, was
derived assuming a binomial distribution using Graph Pad Prism 4
(Graph Pad Software, Inc., San Diego, CA, USA) and/or SPSS
software, version 11.5 (SPSS Inc., Chicago, IL, USA).
The sensitivity determined for biliary brush cytology was
compared with that of the immunofluorometric Mcm5 test using
McNemar’s test for paired proportions. The level of the signal was
compared between patient groups using the Mann–Whitney
U-test. All statistical tests were two-tailed, and a 5% level was
used to indicate statistical significance.
RESULTS
MCM proteins are dysregulated in malignant
pancreaticobiliary disease
The pattern of Mcm2 and -5 protein expression was assessed by
immunohistochemistry in morphologically normal, benign and
malignant biliary and pancreatic tissue derived from biopsies of
masses associated with biliary strictures (Table 1) (Figure 1A–D).
As a positive control for experiments on pancreaticobiliary
tissues, the pattern of Mcm2 and -5 protein expression was
assessed in the colonic crypt as we have described previously
(Stoeber et al, 2001). There was nuclear staining of 70 and 74% of
cells in the lower third of colonic crypts for Mcm2 and Mcm5
respectively, and less than 5% in the upper third (Figure 2A). In
the normal ampulla, which has glands similar to the colon, the
expression of MCM proteins was limited to the basal proliferative
epithelial compartment (Figure 2B).
The expression of Mcm2 and Mcm5 (not shown) was extremely
low in normal pancreas and bile duct (o5% positively stained
nuclei), in keeping with previous observations that reduced
proliferative capacity in stable tissues (e.g., liver and thyroid) is
coupled to repression of origin licensing through downregulation
of MCM helicase subunits (Stoeber et al, 2001). In contrast, in
pancreatic cancer, ampullary carcinoma and cholangiocarcinoma,
high levels of Mcm2 and -5 expression were seen in all tissue layers
indicative of cell-cycle re-entry (Stoeber et al, 1998, 2001; Wharton
et al, 2001). The percentage of nuclei positive for Mcm2 was higher
in malignant tissue (median 76.5%, range 42–92%) than that in
benign tissue (median 5%, range 0–33%) (Po0.0005) (Figure 3).
Similarly, the percentage of nuclei positive for Mcm5 was higher in
malignant strictures (median 91%, range 84–95%, n¼5) than in
benign strictures (median 4%, range 3–8%, n¼5) (not shown).
Mcm5 in bile aspirates compared with routine brush
cytology to diagnose pancreaticobiliary malignancy
Bile aspirates were acquired from 102 patients with biliary
strictures of established (n¼42) or indeterminate aetiology
(n¼60) and the final diagnoses are shown in Table 2. The median
age of the patients was 67 years (33–103 years; M:F 1:1). A final
diagnosis of malignancy was eventually made in 44/60 patients
with indeterminate strictures established by brush cytology
Table 1 Mcm2 expression in masses associated with biliary strictures
Tissue Cases (n¼30) Mcm2 % (range)
Normal pancreas 4 3.5 (0–9.9)
Inflammatory biliary epithelium 5 6 (0–16)
Benign ampulla
a 3 26 (16–38)
Chronic pancreatitis 3 5.5 (0–14)
Pancreatic cancer 5 80 (30–91)
Ampullary cancer 5 56 (40–75)
Cholangiocarcinoma 5 86 (80–92)
Abbreviation: Mcm2¼minichromosome maintenance protein 2.
aNormal ampulla
n¼1, ampulla with chronic inflammation n¼1, villous adenoma with low-grade
dysplasia n¼1.
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s(n¼9), endoscopic ultrasound-fine-needle aspiration (EUS-FNA)
(n¼1), intraductal biopsy (n¼7), percutaneous biopsy (n¼16),
resection specimens (n¼3) or clinical course (n¼8). Two brush
cytology specimens were highly suspicious for malignancy and a
final diagnosis of cancer was made in both. First (i) endoscopic
biopsy performed at the time of brush cytology (n¼20), (ii)
percutaneous biopsy (n¼9) or (iii) EUS-FNA (n¼1) performed
on a separate occasion was obtained in 30/44 patients with
eventual diagnoses of malignant strictures and was positive for
cancer in 13/30 (43%). Fourteen patients with final diagnoses of
malignant strictures underwent a second biopsy/EUS-FNA, which
was positive for cancer in 11/14 (79%). Twenty-four out of
forty-four (55%) patients underwent at least two separate attempts
(range 1–3) at tissue acquisition before malignancy was
confirmed. Benign disease was confirmed by negative pathology
during a mean of 36 (range 21–48) months follow-up.
The performance of the immunofluorometric Mcm5 assay as a
diagnostic test for pancreaticobiliary malignancy in patients with
indeterminate strictures is shown as an ROC curve (Figure 4). The
test discriminated with high accuracy between patients with and
without malignancy, as demonstrated by an area under the ROC
curve of 0.80 (95% CI 0.70–0.91), which was significantly larger
than the area predicted by the null hypothesis (0.5) (Po0.0004). In
other words, a randomly selected patient with pancreaticobiliary
malignancy would have an 80% probability of having an
immunofluorometric Mcm5 value that is greater than that for a
randomly selected patient without malignancy. Three patients with
malignant strictures had bile samples aspirated on two separate
occasions and the mean fluorescence differed by o5%.
AB
CD
Figure 1 Minichromosome maintenance protein 2 expression in benign and neoplastic pancreaticobiliary diseases. (A) Normal pancreas showing absence
of Mcm2 expression. (B) Moderately to poorly differentiated pancreatic adenocarcinoma showing high levels of Mcm2 expression. Occasional viable Mcm2-
negative cells are present. (C) Section of a benign hilar stricture showing occasional Mcm2-positive cells at the base of glands. (D) Moderately to poorly
differentiated cholangiocarcinoma showing high levels of Mcm2 expression. Mcm2¼minichromosome maintenance protein 2.
AB
Figure 2 Immunohistochemistry for Mcm5 in the (A) colonic crypt and
(B) ampulla. At the base of epithelium, nuclei of epithelial cells are positive
for Mcm5 (dark brown) in contrast to surface of epithelium where cells do
not express Mcm5. Mcm5¼minichromosome maintenance protein 5.
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Figure 3 Box-and-whisker plot of range 25th–75th percentile and
median Mcm2 expression in benign and malignant biliary strictures.
Mcm2¼minichromosome maintenance protein 2.
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sEvaluation of the test in comparison with brush cytology in the
60 patients with indeterminate strictures at the time of sample
collection is shown in Table 3 at two different performance levels:
(i) 1000 cells per well (lower detection limit of the assay) and (ii)
1780 cells per well (high specificity). At the 1000-cell cut point, the
test had 66% (29/44) sensitivity and 97% (29/30) positive
predictive value. The Mcm5 test detected 20/44 (45%) additional
cases of cancer that were not detected by brush cytology. At the
1780 cut point, the test had 43% sensitivity and 100% positive
predictive value. The sensitivity and specificity of the Mcm5 test at
the 1000-cell cut point in strictures with established diagnoses
were 62 and 92%, respectively. In patients with a final diagnosis of
a benign stricture, 3/39 (gallstones n¼1, PSC n¼2) had biliary
Mcm5 values greater than 1000 cells per well.
The performance of the immunofluorometric Mcm5 test
according to selected final diagnoses is shown in Table 4. The
Mcm5 immunofluorometric signal for patients with bile duct
stones with or without cholangitis (mediano1000) was not higher
than that for other patients negative for malignancy, where the
median signal was also below the lower detection limit of 1000 cells
per well (Mann–Whitney U-test, P¼0.78). Significant differences
were detected between those samples from patients with cholan-
giocarcinoma (median 1070, P¼0.03) or pancreatic cancer
(median 1490, P¼0.003) and those with inflammatory
strictures (mediano1000). The level of signal was not significantly
different (P¼0.16) between cholangiocarcinoma and pancreatic
cancer.
DISCUSSION
In patients who present with a pancreaticobiliary stricture of
indeterminate origin, biliary brush cytology is the most commonly
used invasive technique to distinguish benign from malignant
disease. The technique offers the clinician almost definitive
diagnostic certainty when positive for malignancy (specificity
96–100%) but has a poor ability to detect malignancy (sensitivity
18–57%) (de Bellis et al, 2002b; Baron et al, 2004; Harewood et al,
2004; Moreno Luna et al, 2006).
This proof of principle study has shown that the sensitivity of
the automated immunofluorometric Mcm5 test on bile aspirates
for detecting pancreaticobiliary malignancy was superior (four
times more at the 1000 cells per well cut point) to that of brush
cytology, while maintaining a high specificity. The high positive
predictive value for malignancy of this test in this group of patients
is of particular importance as a positive test would allow the
clinician to make treatment recommendations with a high degree
of certainty. We have previously shown that the Mcm5 immuno-
fluorometric test is an accurate test for bladder, prostate and
oesophageal cancer (Stoeber et al, 2002; Williams et al, 2004), and
Table 2 Final diagnosis of bile duct strictures in study of Mcm5 test in
bile aspirates
Stricture
Established
diagnoses
(n¼42)
Final diagnoses
of indeterminate
strictures
(n¼60)
Total
(n¼102)
Malignant 18 44 62
Cholangiocarcinoma 12 15 27
Pancreatic cancer 4 19 23
Ampullary carcinoma 0 4 4
Mucinous tumours 2 2 3
Hepatocellular carcinoma 0 1 1
Lymphoma 0 1 1
Metastases to bile duct 0 1 1
Neuroendocrine tumour 0 1 1
Benign 24 16 40
Gallstones 9 5 14
Primary sclerosing cholangitis 6 3 9
Chronic pancreatitis 3 2 5
Autoimmune pancreatitis 0 3 3
Idiopathic 3 1 4
Postoperative 2 1 3
Papillary stenosis 0 0 1
Ampullary adenoma 0 1 1
Abbreviation: Mcm5¼minichromosome maintenance protein 5.
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Figure 4 Receiver operating characteristic curve of immunofluorometric
Mcm5 test. The jagged curve (solid line) is the nonparametric ROC curve.
The diagonal line is the reference line. Area under the curve is 80% (95% CI
70–91). Mcm5¼minichromosome maintenance protein 5; ROC¼recei-
ver operating characteristic.
Table 3 Comparison of the Mcm5 immunofluorometric assay in bile aspirates with brush cytology for the diagnosis of pancreaticobiliary malignancy
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Area under curve (95% CI)
Mcm5 cutoff point 41000 66% (50–79)
a 94% (70–100)
b 97% (90–100) 50% (32–68) 80% (70–91)
Mcm5 cutoff point 41780 43% (29–57) 100% 100% 39 % (24–53) 72% (58–85%)
Brush cytology 20% (7–35)
a 100%
b 100% 31% (18–44) 60% (40–76)
Abbreviations: Mcm5¼minichromosome maintenance protein 5; NPV¼negative predictive value; PPV¼positive predictive value.
aP¼0.004 for sensitivity Mcm5 vs cytology
bP¼not significant.
Table 4 Immunofluorometric Mcm5 test performance in patient groups
Patient group
Group
size (N)
Median
signal
Interquartile
range
Negative for cancer 40 o1000 o1000–o1000
Gallstones 15 o1000 o1000–o1000
Chronic inflammation
a 14 o1000 o1000–o1000
All cancers 62 1198 o1000–3495
Cholangiocarcinoma 27 1070 o1000–2060
Pancreatic cancer 23 1490 o1000–5340
Abbreviation: Mcm5¼minichromosome maintenance protein 5.
aPrimary sclerosing
cholangitis and chronic pancreatitis.
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shere we show its utility for the diagnosis of pancreatic and biliary
tract cancer. Taken together, these studies indicate that the Mcm5
immunofluorometric assay is a robust test to detect exfoliated
malignant cells in body fluids. Moreover, as these malignancies are
associated with different sets of genetic mutations leading to
uncontrolled cell proliferation, this study provides further
evidence supporting the hypothesis that the convergence point of
growth regulatory pathways that control cell proliferation is the
initiation of genome replication in which the MCM complex plays
an essential part.
The median level of expression of Mcm5 in malignant bile
samples was lower than that we detected in urine and oesophageal
aspirates obtained from patients with bladder and oesophageal
cancer respectively (Stoeber et al, 2002; Williams et al, 2004). The
absolute values obtained are however not the most important
factor in determining the usefulness of the test but whether a cutoff
point can be obtained that helps to distinguish between benign and
malignant bile duct strictures by a clinically important margin,
which this test did in the population studied.
Importantly, inflammatory strictures secondary to PSC and
chronic pancreatitis, which are particularly difficult to distinguish
from malignant disease with conventional imaging (Lazaridis and
Gores, 2005; Hamer and Feuerbach, 2006), had median biliary
Mcm5 values below the detection limit of the assay. Benign/normal
tissues did express MCM proteins at low levels (median 5% of cells
stained by immunohistochemistry), but as the cells are located in
the basal epithelium they were probably not exfoliated in bile in
large numbers and therefore not detected by the immunofluoro-
metric test. Interestingly, patients with bile duct stones and
cholangitis – who might be expected to have ulceration and
exposure of the stem-transit compartment of biliary epithelium to
bile – also had a median Mcm5 level in bile below the detection
limit of the assay, reflecting low shedding of reactive Mcm5-
positive cells. This was in contrast to our previous data in patients
with renal calculi and oesophageal ulceration, where the test
detected positive cells in urine and luminal secretions, though of a
magnitude below that of patients with urothelial or oesophageal
carcinoma (Stoeber et al, 2002; Williams et al, 2004).
The immunofluorometric Mcm5 level results in bile were
corroborated by immunohistochemistry data, which showed that
the percentage of nuclei positive for Mcm2 and -5 was higher in
malignant strictures than benign strictures. To date, we have
performed immunohistochemistry on more samples using anti-
Mcm2 than anti-Mcm5 antibodies. The MCM complex consists of
six proteins, all of which are necessary to support initiation of
replication. By detecting the presence of one protein, one can infer
the presence of the other five. However, to verify this we tested 10
cases for both Mcm5 and Mcm2, which showed a similar % of
nuclei positive for MCM proteins.
The molecular diagnosis of pancreaticobiliary malignancies has
been the subject of intensive investigation (Gress, 2004), but to
date few such tests have been developed and incorporated into
routine clinical practice. A recent study of fluorescence in situ
hybridisation to detect chromosomal abnormalities in biliary
brush cytology samples demonstrated results comparable to our
study with a sensitivity of 59–70% and specificity of 86–100% for
the diagnosis of pancreaticobiliary malignancy compared with a
sensitivity of 4–20% for conventional brush cytology (Moreno
Luna et al, 2006).
The sensitivity of biliary brush cytology (20%) in our study is at
the lower end of the range in the published literature although
other published studies (Baron et al, 2004; Harewood et al, 2004;
Moreno Luna et al, 2006) have reported similar sensitivities of
around 20%. One possible explanation is that patients referred to
our centre had small volume, difficult to diagnose tumours, as
demonstrated by the fact that the majority of the first cytology/
biopsy episodes of malignant strictures were negative for cancer.
Bile duct forceps biopsy (Jailwala et al, 2000), EUS-guided FNA of
strictures (Fritscher-Ravens et al, 2004) or a cytopathologist within
the endoscopy room to immediately analyse samples (De Bellis
et al, 2002a) can all independently add to the detection rate of
brush cytology. However, intraductal biopsy, which often requires
a biliary sphincterotomy (Ponchon et al, 1995), and EUS-guided
FNA of strictures are technically challenging procedures with a
higher risk of complications than brush cytology and therefore are
not usual practice in our unit or at other centres (Lee, 2006) when
acquiring tissue for the first time. The advantage of the
immunofluorometric test is that it is based on bile aspirates,
which is technically easier to acquire than all of the methods
mentioned.
The sensitivity of the Mcm5 test depends in part on the
cellularity of bile, which can be acellular in up to 30% of samples
(Mansfield et al, 1997), so that the sensitivity of bile aspirate Mcm5
cannot be expected to reach 100%. In contrast, the cellularity of
brush cytology is much greater than bile aspirates and we are
currently assessing whether cells derived from brush cytology will
further improve the sensitivity of the Mcm5 test. As all cancer
tissues studied expressed MCM proteins, a sensitivity approaching
100% with cells derived from brush cytology applied to the
immunofluorometric Mcm5 test is theoretically achievable. Future
work will aim to replicate these results in a new cohort of patients
and also examine the utility of this test in distinguishing PSC from
cholangiocarcinoma and chronic pancreatitis from pancreatic
cancer in a larger number of patients.
In conclusion, we have demonstrated that immunofluorometric
detection of Mcm5 in bile aspirates is a sensitive and specific
diagnostic test for pancreaticobiliary malignancy. The test detects
a variety of cancer types including those often missed by biliary
brush cytology. This simple method for detecting pancreaticobi-
liary malignancy is now automated allowing for easy translation
into a clinical diagnostic test.
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